Call for Proposals
Cell and Gene Therapy (CGT) has been identified as one of the priority areas under the ‘Precision Biotherapeutics’ vertical of the BioE3 Policy for ‘fostering high performance Biomanufacturing’. The CGT sector is a rapidly evolving field with transformative potential for treatment of a range of complex and previously untreatable diseases. The potential of this emerging therapeutic modality is highlighted by the increasing number of CGTs which have been approved and are also in the development pipeline.